<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="Anti-arhythmic classes   Class I Antiarrhythmics: Class I drugs primarily affect sodium channels and can be further subdivided into three subclasses based on their effects on sodium channels:"><meta property="og:title" content="Cardiovascular drugs"><meta property="og:description" content="Anti-arhythmic classes   Class I Antiarrhythmics: Class I drugs primarily affect sodium channels and can be further subdivided into three subclasses based on their effects on sodium channels:"><meta property="og:type" content="website"><meta property="og:image" content="https://notes.nosos.co.uk/icon.png"><meta property="og:url" content="https://notes.nosos.co.uk/Cardiovascular-drugs/"><meta property="og:width" content="200"><meta property="og:height" content="200"><meta name=twitter:card content="summary"><meta name=twitter:title content="Cardiovascular drugs"><meta name=twitter:description content="Anti-arhythmic classes   Class I Antiarrhythmics: Class I drugs primarily affect sodium channels and can be further subdivided into three subclasses based on their effects on sodium channels:"><meta name=twitter:image content="https://notes.nosos.co.uk/icon.png"><title>Cardiovascular drugs</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://notes.nosos.co.uk//icon.png media="(prefers-color-scheme: dark"><link rel="shortcut icon" type=image/png href=https://notes.nosos.co.uk//icon.png-dark.png media="(prefers-color-scheme: light"><link href=https://notes.nosos.co.uk/styles.61b7f083b0774b0c42e780c0bc55ee73.min.css rel=stylesheet><link href=https://notes.nosos.co.uk/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://notes.nosos.co.uk/js/darkmode.660ec90bf737ee058bec1d99e0222946.min.js></script>
<script src=https://notes.nosos.co.uk/js/util.00639692264b21bc3ee219733d38a8be.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/core@1.2.1></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/dom@1.2.1></script>
<script defer src=https://notes.nosos.co.uk/js/popover.aa9bc99c7c38d3ae9538f218f1416adb.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://notes.nosos.co.uk/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://notes.nosos.co.uk/",fetchData=Promise.all([fetch("https://notes.nosos.co.uk/indices/linkIndex.013331d952e14ce4a5bf04a3cd6b5844.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://notes.nosos.co.uk/indices/contentIndex.b81c7cfeb4acaaed0fecf75bbe9a8a85.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://notes.nosos.co.uk",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!0;drawGraph("https://notes.nosos.co.uk",t,[{"/moc":"#4388cc"}],t?{centerForce:.3,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.2,linkDistance:30,opacityScale:1,repelForce:.5,scale:.9}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()});function a(n){const e=n.target,t=e.className.split(" "),s=t.includes("broken"),o=t.includes("internal-link");plausible("Link Click",{props:{href:e.href,broken:s,internal:o,graph:!1}})}const r=document.querySelectorAll("a");for(link of r)link.className.includes("root-title")&&link.addEventListener("click",a,{once:!0})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/notes.nosos.co.uk\/js\/router.d6fe6bd821db9ea97f9aeefae814d8e7.min.js"
    attachSPARouting(init, render)
  </script><script defer data-domain=notes.nosos.co.uk src=https://plausible.io/js/script.js></script>
<script>window.plausible=window.plausible||function(){(window.plausible.q=window.plausible.q||[]).push(arguments)}</script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://notes.nosos.co.uk/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a class=root-title href=https://notes.nosos.co.uk/>Home</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Cardiovascular drugs</h1><p class=meta>Last updated
Oct 31, 2023
<a href=https://github.com/shaggy2922/quartz/tree/hugo/content/Cardiovascular%20drugs.md rel=noopener>Edit Source</a></p><ul class=tags><li><a href=https://notes.nosos.co.uk/tags/Cardiovascular/>Cardiovascular</a></li></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#anti-platelet>Anti-platelet</a></li><li><a href=#anticoagulants>Anticoagulants</a></li><li><a href=#beta-blockers>$\beta$ blockers</a></li><li><a href=#acei>ACEi</a></li><li><a href=#diuretics>Diuretics</a></li><li><a href=#vasodilators>Vasodilators</a></li><li><a href=#calcium-antagonists>Calcium antagonists</a></li><li><a href=#digoxin>Digoxin</a></li><li><a href=#sodium-channel-blockers>Sodium channel blockers</a></li><li><a href=#amiodarone>Amiodarone</a></li><li><a href=#ivabradine>Ivabradine</a></li><li><a href=#statins>Statins</a></li></ol></nav></details></aside><a href=#anti-arhythmic-classes><h1 id=anti-arhythmic-classes><span class=hanchor arialabel=Anchor># </span>Anti-arhythmic classes</h1></a><ol><li><p>Class I Antiarrhythmics: Class I drugs primarily affect sodium channels and can be further subdivided into three subclasses based on their effects on sodium channels:</p><ul><li>Class IA: These drugs (e.g., quinidine, procainamide, and disopyramide) prolong the action potential duration and are used to treat atrial and ventricular arrhythmias.</li><li>Class IB: These drugs (e.g., lidocaine, mexiletine) have little effect on action potential duration and are used primarily for ventricular arrhythmias.</li><li>Class IC: Drugs like flecainide and propafenone that have minimal effects on action potential duration and are used for both atrial and ventricular arrhythmias.</li></ul></li><li><p>Class II Antiarrhythmics: Class II drugs are beta-blockers (e.g., propranolol, metoprolol, and atenolol) that reduce sympathetic stimulation of the heart. They are used to treat tachyarrhythmias by slowing down the heart rate and reducing the risk of arrhythmias.</p></li><li><p>Class III Antiarrhythmics: Class III drugs primarily affect potassium channels, delaying repolarization of the cardiac cells and prolonging the action potential duration. Examples of Class III antiarrhythmics include amiodarone, sotalol, and dofetilide. These drugs are used to treat a variety of arrhythmias, including atrial and ventricular.</p></li><li><p>Class IV Antiarrhythmics: Class IV drugs are calcium channel blockers (e.g., verapamil and diltiazem). They slow the conduction of electrical signals in the heart by blocking calcium channels. They are primarily used to treat atrial arrhythmias and can also help control ventricular rate in conditions like atrial fibrillation.</p></li><li><p>Other Antiarrhythmics: There are other antiarrhythmic agents that don&rsquo;t fit neatly into the Vaughan Williams classification, including adenosine, digoxin, and some newer drugs. Adenosine is used to terminate certain types of supraventricular tachycardias. Digoxin can be used to control the ventricular rate in atrial fibrillation but is not a first-line antiarrhythmic. Newer agents like dronedarone have been developed and have unique mechanisms of action.</p></li></ol><a href=#anti-platelet><h2 id=anti-platelet><span class=hanchor arialabel=Anchor># </span>Anti-platelet</h2></a><ul><li><strong><em>Aspirin</em></strong> - prevents production of thromboxane A2 inhibiting platelet aggregation. Used in low doses (75mg/day PO) for secondary prevention following <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a>, <a href=/Transient-Ischemic-Attack rel=noopener class=internal-link data-src=/Transient-Ischemic-Attack>Transient Ischemic Attack</a> and <a href=/Stroke rel=noopener class=internal-link data-src=/Stroke>Stroke</a>. Also used for patients with <a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a> or <a href=/peripheral-vascular-disease rel=noopener class=internal-link data-src=/peripheral-vascular-disease>peripheral vascular disease</a>. Also an NSAID and may worsen GI symptoms.</li><li><em><strong>P2Y12 antagonists</strong></em> - (clopidogrel, pasugrel, ticagrelor) also block platelet aggregation but cause less gastric irritation. Used with aspirin after PCI, and in <a href=/Acute-Coronary-Syndrome rel=noopener class=internal-link data-src=/Acute-Coronary-Syndrome>Acute Coronary Syndrome</a></li></ul><a href=#anticoagulants><h2 id=anticoagulants><span class=hanchor arialabel=Anchor># </span>Anticoagulants</h2></a><ul><li><em><strong>DOACs</strong></em> - Xa inhibitors (apixaban), direct thrombin inhibitors (dabigatran) for treatment of <a href=/Atrial-Fibrillation rel=noopener class=internal-link data-src=/Atrial-Fibrillation>Atrial Fibrillation</a> and clots.</li><li>Warfarin is still used for people with mechanical heart valves</li><li>Anticoagulants used in <a href=/Acute-Coronary-Syndrome rel=noopener class=internal-link data-src=/Acute-Coronary-Syndrome>Acute Coronary Syndrome</a> include LMWH, fondaparinux (Xa inhibitor) & bivalirudin (thrombin inhibitor)</li></ul><a href=#beta-blockers><h2 id=beta-blockers><span class=hanchor arialabel=Anchor># </span>$\beta$ blockers</h2></a><ul><li>Antagonise the sympathetic nervous system</li><li>Blocking $\beta_1$ is negatively inotropic and chronotropic</li><li>Blocking $\beta_2$ induces peripheral vasoconstriction and bronchoconstriction</li><li>Propanolol is non selective, bisoprolol is $\beta_1$ selective</li><li>Used in <a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a>, <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a>, post <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a>, <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a></li><li>Contraindicated in <em>severe</em> <a href=/asthma rel=noopener class=internal-link data-src=/asthma>asthma</a>/<a href=/COPD rel=noopener class=internal-link data-src=/COPD>COPD</a>, <a href=/Heart-Block rel=noopener class=internal-link data-src=/Heart-Block>Heart Block</a></li></ul><a href=#acei><h2 id=acei><span class=hanchor arialabel=Anchor># </span>ACEi</h2></a><ul><li>Causes vasodilation and excretion of sodium and water. eg Ramipril</li><li>Used in <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a>, <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a>, post <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a></li><li>Can cause hyperkalaemia</li><li>Put pressure on the kidneys so hold in <a href=/Acute-Kidney-Injury rel=noopener class=internal-link data-src=/Acute-Kidney-Injury>Acute Kidney Injury</a> and monitor U&Es for kidney function</li><li>Can cause a dry cough so may switch to ARB (ARB contraindicated in pregnancy however)</li></ul><a href=#diuretics><h2 id=diuretics><span class=hanchor arialabel=Anchor># </span>Diuretics</h2></a><ul><li><em><strong>Loop diuretics</strong></em> - eg furosemide inhibit NA/2Cl/K co-transporter. $\downarrow$ Na$^+$ $\downarrow$ K$^+$ $\downarrow$ Ca$^{2+}$. <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a></li><li><strong><em>Thiazide/thiazide-like diuretics</em></strong> are used in <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a> (indapamide) and <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a> (metolazone). $\downarrow$ K$^+$ $\uparrow$ Ca$^{2+}$ $\downarrow$ Mg$^{2+}$, $\uparrow$ urate ($\pm$ gout).</li><li><strong>_Potassium sparing diruetics</strong>_ - aldosterone antagonists (spironolactone, eplerenone)</li></ul><a href=#vasodilators><h2 id=vasodilators><span class=hanchor arialabel=Anchor># </span>Vasodilators</h2></a><ul><li>Used in <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a>, <a href=/Coronary-Artery-Disease rel=noopener class=internal-link data-src=/Coronary-Artery-Disease>Ischemic Heart Disease</a>,</li><li><em><strong>Nitrates</strong></em> - preferentially dilate veins and large arteries. $\downarrow$ preload (filling pressure)</li><li><em><strong>Hydralazine</strong></em> - primarily dilate resistance vessels $\downarrow$ after-load (BP)</li><li><em><strong>Prazosin</strong></em> - $\alpha$-blocker dilates veins and arteries</li></ul><a href=#calcium-antagonists><h2 id=calcium-antagonists><span class=hanchor arialabel=Anchor># </span>Calcium antagonists</h2></a><ul><li>$\downarrow$ cell entry of Ca$^{2+}$ in smooth muscle, promoting coronary and peripheral vasodilation and reducing myocardial oxygen use. All current drugs block L-type Ca$^{2+}$ channels but different binding properties cause different effects. <a href=/Essential-hypertension rel=noopener class=internal-link data-src=/Essential-hypertension>hypertension</a> and <a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a></li><li><em><strong>Dihydropyridines</strong></em> - eg <em>amlodipine</em> are mainly peripheral vasodilators and cause a reflex tachycardia so used with a $\beta$-blocker</li><li><em><strong>Non-dihydropyridines</strong></em> - eg <em>verapamil and diltiazem</em> slow conduction at the AV and SV node and may be used to treat dysrhythmias in addition.</li></ul><blockquote class=info-callout><p>Don&rsquo;t give non-dihydropyridines with $\beta$-blockers for risk of severe bradycardia</p></blockquote><a href=#digoxin><h2 id=digoxin><span class=hanchor arialabel=Anchor># </span>Digoxin</h2></a><ul><li>Blocks the Na+/K+ pump. Used to rate control in fast <a href=/Atrial-Fibrillation rel=noopener class=internal-link data-src=/Atrial-Fibrillation>AF</a> (aim for less than 100)</li><li>Weak +ve inotrope, half life of 36 hours</li><li>$\uparrow$ Toxicity risk if $\downarrow$ K$^+$ $\downarrow$ Mg$^{2+}$ or $\uparrow$ Ca$^{2+}$</li><li>May caused ST depression in toxicity <a href=/ECG-Lead-Placement-Interpretation#20b905 rel=noopener class=internal-link data-src=/ECG-Lead-Placement-Interpretation>Digoxin effect</a></li></ul><a href=#sodium-channel-blockers><h2 id=sodium-channel-blockers><span class=hanchor arialabel=Anchor># </span>Sodium channel blockers</h2></a><ul><li>Class I anti-arrhythmics</li><li><em><strong>Procainamide (1a) and Lidocaine (1b)</strong></em> can be used to terminate VT</li><li><em><strong>Flecainide (1c)</strong></em> is useful for <a href=/Atrial-Fibrillation rel=noopener class=internal-link data-src=/Atrial-Fibrillation>Atrial Fibrillation</a> cardioversion and for anti-arrhythmia prophylaxis</li><li>Contraindicated in <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a>, <a href=/Coronary-Artery-Disease rel=noopener class=internal-link data-src=/Coronary-Artery-Disease>Ischemic Heart Disease</a>, <a href=/Heart-Block rel=noopener class=internal-link data-src=/Heart-Block>Heart Block</a>, and valve disease</li></ul><a href=#amiodarone><h2 id=amiodarone><span class=hanchor arialabel=Anchor># </span>Amiodarone</h2></a><ul><li>Class III anti-arrhythmic</li><li>Prolongs cardiac action potential reducing the chance for tacharrythmias</li><li>Used in SVT and VT</li><li>Broad side effects - thyroid disease, liver disease, <a href=/Pulmonary-Fibrosis rel=noopener class=internal-link data-src=/Pulmonary-Fibrosis>Pulmonary Fibrosis</a> and peripheral neuropathy</li><li>Monitor TFTs and LFTs every 6 months</li></ul><a href=#ivabradine><h2 id=ivabradine><span class=hanchor arialabel=Anchor># </span>Ivabradine</h2></a><ul><li>Blocks the pacemaker funny current (small current to give the heart a push to make a contraction). So slows pulse rate without significantly dropping blood pressure</li><li><a href=/Angina rel=noopener class=internal-link data-src=/Angina>Angina</a>, <a href=/Heart-Failure rel=noopener class=internal-link data-src=/Heart-Failure>Heart Failure</a> and off licence in autonomic tachycardia syndromes</li><li>CI in acute <a href=/myocardial-infarction rel=noopener class=internal-link data-src=/myocardial-infarction>myocardial infarction</a>, long QT, bradycardia.</li><li>Many drug interactions including with calcium antagonists</li></ul><a href=#statins><h2 id=statins><span class=hanchor arialabel=Anchor># </span>Statins</h2></a><ul><li>Inhibit HMG-CoA reductase preventing de novo synthesis of cholesterol in the liver. This increases LDL receptor expression on hepatocytes leading to $\downarrow$ LDL cholesterol.</li><li>More effective if given at night</li><li>Generally v well tolerated</li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/Angina/ data-ctx="Cardiovascular drugs" data-src=/Angina class=internal-link>Angina</a></li></ul></div><div><script src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://notes.nosos.co.uk/js/graph.6579af7b10c818dbd2ca038702db0224.js></script></div></div><div id=contact_buttons><footer><p>Evan McNab © 2024</p><ul><li><a href=https://notes.nosos.co.uk/>Home</a></li><li><a href=https://www.nosos.co.uk/>Nosos</a></li><li><a href=https://notes.nosos.co.uk/tags/>Tags</a></li></ul></footer></div></div></body></html>